Do patients receiving EGFR targeted therapy for metastatic NSCLC have improved outcomes with the addition of radiation? In this multicenter, randomized phase 2 trial from China, 62 patients with metastatic, EGFR-mutant NSCLC who had at least stable disease on 3 months of first-line EGFR-TKI therapy at the time (gefitinib, erlotinib, or icotinib) were randomized to continue standard therapy with or without SBRT. The targets were chosen at physician discretion and could include the primary, metastatic sites, or both. They received 30-50 Gy in 5 fractions. EGFR-TKIs were continued during SBRT. The addition of SBRT significantly increased median PFS from 9 to 17.6 months and OS from 23.2 to 33.6 months. These results are similar to the improvements seen when combining radiation and EGFR-TKIs in the SINDAS trial. | Peng, Radiother Oncol 2023
